Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Vey

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Clinical Neuropharmacology|August 1, 2009
Experimental conditions substantially influence botulinum toxin potency testingGerd Mander, Klaus Fink, Martin Vey
Toxicon : Official Journal of the International Society on Toxinology|January 4, 2011
Studies on the dissociation of botulinum neurotoxin type A complexesKarl-Heinz Eisele, Klaus Fink, Martin Vey, et al.
The Lancet. Neurology|November 22, 2005
Coexistence of multiple PrPSc types in individuals with Creutzfeldt-Jakob diseaseMagdalini Polymenidou, Katharina Stoeck, Markus Glatzel, et al.
The Journal of Cell Biology|August 20, 2003
Trafficking of prion proteins through a caveolae-mediated endosomal pathwayPeter J Peters, Alexander Mironov, David Peretz, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 3, 2005
Diagnosis of human prion diseaseJiri G Safar, Michael D Geschwind, Camille Deering, et al.
Plos One|January 4, 2022
IgG3 and IgM Identified as Key to SARS-CoV-2 Neutralization in Convalescent Plasma PoolsChristina Kober, Sandro Manni, Svenja Wolff, et al.
Plos One|December 9, 2008
The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopesMagdalini Polymenidou, Rita Moos, Mike Scott, et al.
Alternatives to Laboratory Animals : ATLA|September 9, 2010
The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert MeetingSarah Adler, Gerd Bicker, Hans Bigalke, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Clinical Neuropharmacology|August 1, 2009
Experimental conditions substantially influence botulinum toxin potency testingGerd Mander, Klaus Fink, Martin Vey
Toxicon : Official Journal of the International Society on Toxinology|January 4, 2011
Studies on the dissociation of botulinum neurotoxin type A complexesKarl-Heinz Eisele, Klaus Fink, Martin Vey, et al.
The Lancet. Neurology|November 22, 2005
Coexistence of multiple PrPSc types in individuals with Creutzfeldt-Jakob diseaseMagdalini Polymenidou, Katharina Stoeck, Markus Glatzel, et al.
The Journal of Cell Biology|August 20, 2003
Trafficking of prion proteins through a caveolae-mediated endosomal pathwayPeter J Peters, Alexander Mironov, David Peretz, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 3, 2005
Diagnosis of human prion diseaseJiri G Safar, Michael D Geschwind, Camille Deering, et al.
Plos One|January 4, 2022
IgG3 and IgM Identified as Key to SARS-CoV-2 Neutralization in Convalescent Plasma PoolsChristina Kober, Sandro Manni, Svenja Wolff, et al.
Plos One|December 9, 2008
The POM monoclonals: a comprehensive set of antibodies to non-overlapping prion protein epitopesMagdalini Polymenidou, Rita Moos, Mike Scott, et al.
Alternatives to Laboratory Animals : ATLA|September 9, 2010
The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert MeetingSarah Adler, Gerd Bicker, Hans Bigalke, et al.
Pageof 1